Asceneuron
Develops effective therapeutics for orphan tauopathies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $100m | Series C | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 1 % | (8 %) | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Asceneuron is an emerging biotech company focused on discovering and developing groundbreaking therapeutics for neurodegenerative disorders, particularly those with high unmet medical needs such as orphan tauopathies and other related diseases. The company operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from central nervous system (CNS) disorders. Asceneuron's business model revolves around research and development (R&D) of innovative small molecules that have the potential to halt and prevent neurodegeneration. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products. Asceneuron's R&D pipeline is designed to address significant gaps in current treatment options, aiming to improve patients' lives by providing effective solutions for complex brain diseases. The company actively participates in industry conferences and collaborates with leading experts to stay at the forefront of CNS therapeutic development.
Keywords: neurodegenerative, therapeutics, CNS disorders, tauopathies, biotech, small molecules, R&D, brain diseases, innovative, partnerships.